SG11201810687SA - Serum albumin-binding fibronectin type iii domains - Google Patents

Serum albumin-binding fibronectin type iii domains

Info

Publication number
SG11201810687SA
SG11201810687SA SG11201810687SA SG11201810687SA SG11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA
Authority
SG
Singapore
Prior art keywords
domains
international
serum albumin
johnson
rule
Prior art date
Application number
SG11201810687SA
Inventor
Michael Diem
Steven Jacobs
Karyn O'neil
Thomas Rutkoski
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201810687SA publication Critical patent/SG11201810687SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2 3 4 5 6 7 8 9 10 11 12 .* Serum Albumin .* * Centyrins '* Cyno Serum Human Serum W O 20 17 / 210 425 Al • • I • • I (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) W I POI PCT ill~~~~~~~~ 011101tIIl tun Hol milomonnom oimIE (10) International Publication Number WO 2017/210425 Al (51) International Patent Classification: A61K 38/38 (2006.01) C07K 14/78 (2006.01) A61K 38/39 (2006.01) (21) International Application Number: PCT/US2017/035442 (22) International Filing Date: 01 June 2017 (01.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,190 03 June 2016 (03.06.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US). (72) Inventors: DIEM, Michael; 1400 McKean Road, Spring- house, PA 19477 (US). JACOBS, Steven; 1400 McK- ean Road, Springhouse, PA 19477 (US). O'NEIL, Karyn; 1400 McKean Road, Springhouse, PA 19477 (US). RUTKOSKI, Thomas; 1400 McKean Road, Springhouse, PA 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS Figure 1 (57) : Fibronectin type III domains (FN3) that specifi- cally bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications. [Continued on next page] WO 2017/210425 Al MIDEDIMOMMIDIRMEM001101011fillIONVOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201810687SA 2016-06-03 2017-06-01 Serum albumin-binding fibronectin type iii domains SG11201810687SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345190P 2016-06-03 2016-06-03
PCT/US2017/035442 WO2017210425A1 (en) 2016-06-03 2017-06-01 Serum albumin-binding fibronectin type iii domains

Publications (1)

Publication Number Publication Date
SG11201810687SA true SG11201810687SA (en) 2018-12-28

Family

ID=60477987

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810687SA SG11201810687SA (en) 2016-06-03 2017-06-01 Serum albumin-binding fibronectin type iii domains

Country Status (13)

Country Link
US (3) US10925932B2 (en)
EP (1) EP3463430A4 (en)
JP (2) JP7111627B2 (en)
KR (1) KR102461666B1 (en)
CN (1) CN109562146A (en)
AU (1) AU2017273743B2 (en)
EA (1) EA201892796A1 (en)
IL (2) IL263347B (en)
MA (1) MA45186A (en)
MX (1) MX2018014876A (en)
SG (1) SG11201810687SA (en)
UA (1) UA126021C2 (en)
WO (1) WO2017210425A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102478402B1 (en) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 Cysteine engineered fibronectin type iii domain binding molecules
EA201892796A1 (en) * 2016-06-03 2019-06-28 Янссен Байотек, Инк. CONNECTING WITH SERUM ALBUMIN DOMAINS FIBRONECTIN TYPE III
CN109689080A (en) * 2016-06-21 2019-04-26 詹森生物科技公司 Cysteine is engineered type III fibronectin domain binding molecule
CN110225770B (en) 2016-12-14 2022-04-26 杨森生物科技公司 Fibronectin type III domain binding to CD8A
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN110724198B (en) * 2018-07-17 2023-05-26 上海一宸医药科技有限公司 Long acting fibronectin type III domain fusion proteins
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN114786682A (en) * 2019-10-14 2022-07-22 Aro生物疗法公司 Fibronectin type III domain of CD71
USD1021702S1 (en) * 2021-10-20 2024-04-09 GM Global Technology Operations LLC Vehicle center grille

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) * 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
FR2646437B1 (en) * 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0494955B1 (en) * 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69329503T2 (en) * 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
ES2301198T3 (en) * 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. ARTIFICIAL POLYPEPTIDES OF ANTIBODIES.
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6472147B1 (en) * 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
JP4602614B2 (en) * 2001-09-26 2010-12-22 アイシン精機株式会社 Automotive door
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
WO2004022746A1 (en) 2002-09-06 2004-03-18 Isogenica Limited In vitro peptide expression libraray
WO2009085462A1 (en) * 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
CA2710378A1 (en) * 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
KR101781907B1 (en) * 2008-10-31 2017-09-26 얀센 바이오테크 인코포레이티드 Fibronectin type iii domain based scaffold compositions, methods and uses
EP2396011B1 (en) * 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
KR101863033B1 (en) * 2010-04-30 2018-06-01 얀센 바이오테크 인코포레이티드 Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) * 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP4151785A1 (en) * 2011-09-27 2023-03-22 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
MX2016007533A (en) * 2013-12-09 2016-12-14 Univ New York Compositions and methods for phagocyte delivery of anti-staphylococcal agents.
CN113150117A (en) * 2014-03-20 2021-07-23 百时美施贵宝公司 Novel serum albumin binding fibronectin type III domain
WO2016197071A1 (en) * 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
EA201892796A1 (en) * 2016-06-03 2019-06-28 Янссен Байотек, Инк. CONNECTING WITH SERUM ALBUMIN DOMAINS FIBRONECTIN TYPE III
CN109689080A (en) * 2016-06-21 2019-04-26 詹森生物科技公司 Cysteine is engineered type III fibronectin domain binding molecule

Also Published As

Publication number Publication date
WO2017210425A1 (en) 2017-12-07
EA201892796A1 (en) 2019-06-28
CN109562146A (en) 2019-04-02
UA126021C2 (en) 2022-08-03
KR20190013970A (en) 2019-02-11
EP3463430A1 (en) 2019-04-10
JP2022046510A (en) 2022-03-23
JP7111627B2 (en) 2022-08-02
IL282960A (en) 2021-06-30
IL263347A (en) 2018-12-31
AU2017273743B2 (en) 2021-12-02
IL263347B (en) 2021-05-31
US20210228688A1 (en) 2021-07-29
US20240100129A1 (en) 2024-03-28
IL282960B (en) 2022-03-01
US11833190B2 (en) 2023-12-05
MA45186A (en) 2019-04-10
JP2019521662A (en) 2019-08-08
KR102461666B1 (en) 2022-11-01
AU2017273743A1 (en) 2019-01-03
US10925932B2 (en) 2021-02-23
MX2018014876A (en) 2019-05-22
EP3463430A4 (en) 2020-02-12
US20170348397A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201806398YA (en) Optimized factor viii genes
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201907209QA (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201901140QA (en) Compounds and methods for reducing tau expression
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201408054RA (en) Pegylated oxm variants
SG11201901411VA (en) Conditionally active polypeptides and methods of generating them
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16